Core Points - The company held its 18th meeting of the third board of directors on August 21, 2025, where all 7 attending directors approved the resolutions presented [1][2] - The board approved the 2025 semi-annual report and its summary, confirming that the report complies with relevant laws and accurately reflects the company's situation [1][2] - The board also approved a proposal for asset impairment provision, stating that it aligns with accounting standards and the company's policies [2]

证券代码：002901 证券简称：大博医疗 公告编号：2025-032 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）第三届监事会第十七次会议 于 2025 年 8 月 21 日在公司会议室以现场方式召开，会议通知以专人送达、传真、 电子邮件、电话相结合的方式已于 2025 年 8 月 11 日向各位监事发出，本次会议 应参加监事 3 名，实际参加监事 3 名，本次会议的召开符合《公司法》《公司章 程》等法律法规的规定，合法有效。 本次会议由监事会主席詹欢欢女士主持，与会监事就会议议案进行了审议、 表决，形成了如下决议： 二、会议以 3 票同意、0 票反对、0 票弃权的表决结果审议通过《关于计提 资产减值准备的议案》。 经审核，监事会认为：本次计提资产减值准备事项，遵循了谨慎性原则，符 合《企业会计准则》、公司会计政策的规定及公司资产实际情况，该事项的决策 程序合法、依据充分，本次计提资产减值准备事项能够更加公允地反应公司的资 产状况和经营成果。监事会同意公司本次计提资产减值准备。 大博医疗科技股份有限公司 具体内 ...

Core Viewpoint - The report highlights the financial performance and operational status of Double Medical Technology Inc. for the first half of 2025, showcasing significant growth in revenue and net profit, alongside a stable business model in the medical high-value consumables sector. Financial Performance - The company achieved operating revenue of CNY 1,210,439,721.50, representing a year-on-year increase of 25.55% compared to CNY 964,129,205.76 in the same period last year [2][10]. - The net profit attributable to shareholders reached CNY 244,258,762.40, up 76.69% from the previous year, while the net profit after deducting non-recurring gains and losses was CNY 222,695,524.72, reflecting an increase of 82.64% [2][10]. - The basic earnings per share increased by 79.90% to CNY 0.6007 from CNY 0.3339 [2][10]. - The overall gross margin for the reporting period was 71.01% [10]. Business Overview - The main business of the company involves the production, research, and sales of medical high-value consumables, including orthopedic trauma implants, spinal implants, joint implants, sports medicine, and minimally invasive surgical consumables [3][4]. - The company’s product lines showed collaborative growth, with trauma products generating CNY 468,220,039.78 in revenue, a 23.68% increase, and spinal products achieving CNY 217,257,515.06, up 29.86% [10][11]. International Expansion - The company has been actively expanding its international market presence, with products exported to over 70 countries, including Australia, Ukraine, and Chile. The overseas business revenue reached CNY 157,583,735.84, marking a 50.84% increase [11][12]. R&D and Quality Management - The company has established a comprehensive R&D system, holding 110 invention patents and 251 medical device registration certificates, with some products certified by FDA and CE [12][14]. - A strict quality management system is in place to ensure product reliability and safety, which is critical for maintaining the company's reputation in the medical field [14]. Marketing and Sales Strategy - The company employs a distribution-focused sales model, supported by a robust marketing network across more than 30 provinces in China, enhancing its market influence and brand recognition [15][16]. - The marketing strategy includes training programs for distributors and direct engagement with healthcare professionals to promote product awareness and usage [10][11].

| | | 大博医疗科技股份有限公司2025年半年度报 | | | --- | --- | --- | --- | | 告摘要 | | | | | 证券代码：002901 证券简称：大博医疗 | | | 公告 | | 编号：2025-029 | | | | | 大博医疗科技股份有限公司 2025 年半年度报告摘要 | | | | | 一、重要提示 | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 | | | | | 资者应当到证监会 | | | | | 指定媒体仔细阅读半年度报告全文。 | | | | | 所有董事均已出席了审议本报告的董事会会议。 | | | | | 非标准审计意见提示 | | | | | □适用 √ 不适用 | | | | | 董事会审议的报告期利润分配预案或公积金转增股本预案 | | | | | √ □适用 不适用 | | | | | 公司计划不派发现金红利，不送红股，不以公积金转增股本。 | | | | | 董事会决议通过的本报告期优先股利润分配预案 | | | | | □适用 √ 不适用 | | | | | 二、公司基本情 ...

Group 1 - The core viewpoint of the article is that Dabo Medical (002901.SZ) has shown significant growth in its financial performance for the first half of 2025, with notable increases in both revenue and net profit [1] - The company's operating revenue reached 1.21 billion yuan, representing a year-on-year growth of 25.55% [1] - The net profit attributable to shareholders of the listed company was 244 million yuan, reflecting a year-on-year increase of 76.69% [1] Group 2 - The net profit attributable to shareholders after deducting non-recurring gains and losses was 223 million yuan, which is an increase of 82.64% year-on-year [1] - The basic earnings per share for the company stood at 0.6007 yuan [1]

Company Overview - Dabo Medical focuses on the research, production, and sales of high-value consumables for orthopedic implants, covering trauma, spine, and joint fields [1]. Financial Performance - For the first half of 2025, Dabo Medical reported a revenue of 1.21 billion yuan, representing a year-on-year growth of 25.55% [1]. - The net profit attributable to shareholders reached 244 million yuan, showing a significant increase of 76.69% year-on-year [1]. - Revenue from trauma products was 468 million yuan, up 23.68% year-on-year, while spine product revenue was 217 million yuan, reflecting a growth of 29.86% [1]. Market Activity - As of August 21, 2025, Dabo Medical's stock price closed at 58.50 yuan, down 0.37% from the previous trading day [1]. - The trading volume for the day was 270 million yuan, with a price fluctuation of 1.87% [1]. - On August 21, the net inflow of main funds was 9.74 million yuan, while the net outflow over the past five days totaled 112 million yuan [1].

格隆汇8月21日丨大博医疗(002901.SZ)公布2025年半年度报告，上半年公司实现营业收入12.10亿元，同 比增长25.55%；归属于上市公司股东的净利润2.44亿元，同比增长76.69%；归属于上市公司股东的扣除 非经常性损益的净利润2.23亿元，同比增长82.64%；基本每股收益0.6007元。 ...

来源：金融界 通过天眼查大数据分析，大博医疗科技股份有限公司共对外投资了24家企业，参与招投标项目942次； 知识产权方面有商标信息24条，专利信息340条；此外企业还拥有行政许可260个。 大博医疗半年报数据显示，2025年1-6月营业总收入为12.1亿元，较去年同期增长25.55%，净利润为2.44 亿，较去年同期增长76.69%，每股收益0.6007元，净资产收益率为7.6%，每股经营现金流量为0.6348 元，销售毛利率为71.01%，所处行业为医疗器械。 资料显示，大博医疗成立于2004年，位于厦门市海沧区山边洪东路18号，是一家以从事医用高值耗材的 生产、研发与销售为主的企业。企业注册资本4.14亿人民币，法人代表为林志雄。 ...

Core Insights - Dabo Medical (002901.SZ) reported a revenue of 1.21 billion yuan for the first half of 2025, representing a year-on-year growth of 25.55% [1] - The net profit attributable to shareholders reached 244 million yuan, marking a significant increase of 76.69% compared to the previous year [1] - The basic earnings per share stood at 0.60 yuan [1] Revenue Breakdown - The trauma product line generated revenue of 468 million yuan, reflecting a year-on-year growth of 23.68% [1] - The spinal product line achieved revenue of 217 million yuan, with a year-on-year increase of 29.86% [1]

证券代码：002901 证券简称：大博医疗 公告编号：2025-030 大博医疗科技股份有限公司 关于计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 大博医疗科技股份有限公司（以下简称"公司"）于2025年8月21日召开第 三届董事会第十八次会议、第三届监事会第十七次会议，审议通过了《关于计提 资产减值准备的议案》。现将具体情况公告如下： 一、计提资产减值准备情况概述 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第1号——主板上市公司规范运作》《企业会计准则》等相关规定，为真实、 准确地反映公司截至2025年6月30日的财务状况及2025年半年度的经营成果，基 于谨慎性原则，经对公司及下属子公司的各项金融资产、存货和长期资产等进行 全面充分的分析、评估和减值测试后，公司对预期可能发生信用减值损失和资产 减值损失的相关资产计提减值准备。拟于2025年半年度确认的信用减值损失和资 产减值损失如下列示： 单位：万元 项 目 期初余额 计提 其他 转回/核销 期末余额 信 用 减 值损失 应收账款坏账准备 4,645 ...